Skip to main content
Cidara Therapeutics, Inc. logo

Cidara Therapeutics, Inc. — Investor Relations & Filings

Ticker · CDTX ISIN · US1717572069 LEI · 549300IHQ9Z7RI1X2D22 US Manufacturing
Open in API
Filings indexed 793 across all filing types
Latest filing 2024-09-14 Director's Dealing
Country US United States of America
Listing US CDTX

About Cidara Therapeutics, Inc.

https://www.cidara.com/

Cidara Therapeutics, Inc. is a biotechnology company that develops targeted immunotherapies and novel anti-infectives for patients with serious diseases. The company utilizes its proprietary Cloudbreak® platform to create drug-Fc conjugates (DFCs). These DFCs are engineered as 'single molecule cocktails' by coupling targeted small molecules or peptides to a human antibody fragment (Fc). This approach is designed to directly inhibit disease targets, such as fungal or viral pathogens, while simultaneously engaging the patient's immune system. The company's focus is on developing therapies for the treatment and prevention of life-threatening infections and other serious conditions.

Recent filings

Filing Released Lang Actions
FORM 4
Director's Dealing
2024-09-14 English
FORM 4
Director's Dealing
2024-09-14 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Regulatory Filings Classification · 100% confidence The document is a Form 8-K Current Report filed with the SEC, dated September 9, 2024. It reports a workforce reduction and related costs, as well as updates on clinical trial plans. The content is a specific event disclosure rather than a full financial report or earnings release. It does not contain comprehensive financial statements or detailed financial analysis. The Form 8-K is used for current event reporting and is classified under Regulatory Filings (RNS) as it does not fit into other specific categories like earnings release or management reports. The document length is 5678 characters, which is consistent with a typical 8-K filing. Therefore, the appropriate classification is Regulatory Filings (RNS).
2024-09-12 English
CIDARA THERAPEUTICS, INC. FORM S-8
Regulatory Filings Classification · 100% confidence The document is a Form S-8 Registration Statement filed with the SEC by Cidara Therapeutics, Inc. on August 13, 2024. Form S-8 is used to register securities to be offered under employee benefit plans, such as equity incentive plans and inducement plans. The text includes detailed descriptions of the equity incentive plans, the number of shares registered, and references to prior filings and exhibits. It is not a financial report, earnings release, or management discussion, but a regulatory filing related to securities registration under the Securities Act of 1933. Therefore, it fits best under the category of Regulatory Filings (RNS), which is the fallback for miscellaneous SEC filings that do not fit other categories.
2024-08-13 English
CIDARA THERAPEUTICS, INC. FORM 8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K Current Report filed with the SEC by Cidara Therapeutics, Inc. It reports the issuance of a press release with financial results for the second quarter ended June 30, 2024. The document itself does not contain detailed financial statements or substantive financial data but rather references the press release as an exhibit. The length is 3712 characters, which is relatively short and consistent with an announcement rather than a full financial report. According to the 'Menu vs Meal' rule, this is an announcement of financial results, not the full earnings release or quarterly report itself. Therefore, the appropriate classification is Earnings Release (ER), as the document announces quarterly financial results via a press release.
2024-08-13 English
CIDARA THERAPEUTICS, INC. FORM 10-Q
Interim / Quarterly Report Q2 2024
2024-08-13 English

Browse filings by year

13 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.